Insilico Medicine
the Pharma.AI / Chemistry42 platform; its generative-AI-discovered TNIK inhibitor ISM001-055 (rentosertib) for idiopathic pulmonary fibrosis reported positive Phase IIa topline results (published in Nature Medicine) and is advancing toward pivotal trials — a flagship AI-designed asset.
- Country
- China
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| AI drug design & AlphaFold applications | therapeutics-platforms | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.